Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($1.24). Revenue for the quarter came in at $35.07 million.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- Deutsche Bank Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
